Multi-biomarker approach for predicting cardiac magnetic resonance parameters at 30 days after ST-segment elevation myocardial infarction Tim Horbach, Florian A. Wenzl, Robert Manka, Lorenz Räber, David Carballo, Till Keller, Samuel Sossalla, Frank Ruschitzka, Arnold von Eckardstein, Barbara E. Stähli, Thomas F. Lüscher, Roland Klingenberg Ijc Heart and Vasculature, 2026 A graphical summary of the design and the major findings from the study are shown. Abbreviations: hsTnT, high sensitivity troponin T; NT-proBNP, N-terminal pro Brain Natriuretic Peptide; CCN1, cellular communication network factor 1; PCSK9, Proprotein Convertase Subtilisin/Kexin Type 9. • In this pre-specified substudy of the Controlled Level Everolimus in Acute Coronary Syndromes (CLEVER-ACS) randomized controlled trial, we evaluated whether baseline biomarkers are associated with 30-day CMR infarct phenotype, including functional, scar-related, structural, and microvascular parameters. • Major Findings: • Baseline high-sensitivity troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) showed the strongest associations with clinically relevant 30-day CMR-derived infarct characteristics, including left ventricular ejection fraction (LVEF), scar mass, left ventricular scar, and microvascular obstruction. • Cellular communication network factor 1 (CCN1) and proprotein convertase subtilisin/kexin type 9 (PCSK9) did not provide meaningful discriminatory performance in this 30-day setting. Established biomarkers are used for risk stratification after STEMI, but their relationship with cardiac magnetic resonance (CMR)-derived infarct characteristics at 30 days remains incompletely understood. Because 30-day CMR reflects an intermediate post-infarction stage between acute myocardial injury and the later chronic infarct state, we evaluated whether baseline high-sensitivity troponin T (hsTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), cellular communication network factor 1 (CCN1), and proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with 30-day CMR parameters. In this pre-specified CLEVER-ACS substudy, associations between baseline biomarkers and 30-day CMR parameters were assessed using Spearman correlation. Receiver operating characteristic (ROC) analysis with area under the curve (AUC) was performed for associations after median dichotomization. Exploratory analyses assessed associations with relative CMR changes. 56 STEMI patients were analyzed. hsTnT and NT-proBNP showed the strongest association pattern across functional, structural, volumetric, and microvascular 30-day CMR parameters. CCN1 was associated only with left ventricular ejection fraction (LVEF), and PCSK9 showed no significant associations. hsTnT and NT-proBNP showed relevant discriminatory performance for parameters including LVEF (AUC 0.79, 95% CI 0.67–0.91, and 0.81 [0.69–0.93]), left ventricular scar (0.87 [0.77–0.96] and 0.76 [0.63–0.89]), scar mass (0.84 [0.74–0.95] and 0.79 [0.67–0.91]), and microvascular obstruction (0.72 [0.56–0.87] and 0.71 [0.55–0.86]), respectively. Exploratory analyses linked only hsTnT and NT-proBNP to changes in CMR parameters. Baseline hsTnT and NT-proBNP showed strong associations with 30-day CMR parameters after STEMI, whereas CCN1 and PCSK9 provided no discriminatory value in this intermediate post-infarction stage.
C-reactive protein and cardiovascular risk in the general population Berkan Kurt, Martin Reugels, Kai M Schneider, Jens Spiesshoefer, Andrea Milzi, Alexander Gombert, Christopher B Fordyce, Florian A Wenzl, Neha J Pagidipati, Viviane Rocha, Marat Fudim, Abhinav Sharma, Michael Lehrke, Hiroaki Shimokawa, Giovanna Liuzzo, Lale Tokgozoglu, Filippo Crea, Thomas F Lüscher, Peter Libby, Paul M Ridker, Nikolaus Marx, Carolin V Schneider, Florian Kahles European Heart Journal, 2026 Background and Aims High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation and predicts cardiovascular (CV) risk in individuals without known atherosclerotic CV disease (ASCVD). More information about its clinical relevance will help evaluate the general utility of hsCRP as a routine clinical biomarker to identify patients at residual risk. Methods In this population-based study, hsCRP was measured in 448 653 UK Biobank participants without known ASCVD. The association of hsCRP with major adverse cardiovascular events (MACE), CV death and all-cause death was assessed using Cox proportional hazards models. Results The cohort had a median age of 57 years, 55.4% were female, and median hsCRP levels were 1.32 mg/L. A repeat hsCRP measurement in 15 967 participants after 4.4 years showed long-term stability. In covariate-adjusted models individuals with hsCRP levels >3 mg/L had a 34% higher risk of MACE, a 61% and 54% increased risk of CV death and all-cause death compared to those with hsCRP <1 mg/L. Subjects with hsCRP levels ≥2 mg/L vs <2 mg/L had a 22% increased risk of MACE, and a 37% and 34% higher risk of CV death and all-cause death. The association of hsCRP with all endpoints was consistent across subgroups. Predictive performance of hsCRP ranked above conventional risk factors. Integration of hsCRP improved SCORE2 and provided a total net reclassification improvement of 14.1% for prediction of MACE. Conclusions These data confirm hsCRP as a clinically relevant predictor of CV events in individuals without known ASCVD and support its assessment in primary prevention.
Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study Florian A Wenzl, Kok Weng Ow, Matthijs A Velders, Freya Tyrer, Lizz Paley, Jennifer Lai, Maria A Smolle, Victor Schweiger, Emil Hagström, Mark A de Belder, Peizhi Wang, Antanas Gasys, Moa Simonsson, Clive Weston, Davide Di Vece, Christian Templin, Hans Rickli, Dragana Radovanovic, Thomas M Suter, Lorenz Räber, Michael D Peake, John Deanfield, Stefan James, David Adlam, Thomas F Lüscher Lancet, 2026 BACKGROUND: Accurate assessment of mortality, bleeding, and atherothrombotic risk in patients with cancer and acute coronary syndrome could inform novel personalised treatment strategies, but no standardised tools for this purpose exist. We aimed to develop and validate a clinically applicable risk score for mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome. METHODS: In this model development and validation study, we obtained data for 1 017 759 patients who presented with acute coronary syndrome in England, UK (n=815 170; 36 771 with cancer), Sweden (n=194 059; 10 262 with cancer), and Switzerland (n=8530; 203 with cancer) between Jan 1, 2004, and Aug 8, 2023. Machine learning models were developed to predict all-cause mortality, major bleeding events, and ischaemic events, defined as a composite of cardiovascular death, myocardial infarction, and ischaemic stroke, in patients with cancer and acute coronary syndrome from England in a competing risks framework with a prediction horizon of 6 months. Final models (the ONCO-ACS score) were externally validated in geographically distinct held out datasets from the English Midlands, Sweden, and Switzerland. FINDINGS: Patients with cancer and with acute coronary syndrome were characterised by high rates of mortality (cumulative incidence 27·8% [95% CI 27·3-28·3]), major bleeding (7·3% [7·0-7·5]), and ischaemic events (16·1% [15·7-16·4]) and had a distinct risk profile. The ONCO-ACS score was informed by a single set of variables: tumour type, time since cancer diagnosis, metastatic disease, age, haemoglobin, heart rate, estimated glomerular filtration rate, BMI, Killip class, cardiac arrest, and major bleed within 6 months. Accounting for traditional and cancer-related risk factors, ONCO-ACS showed a time-dependent area under the receiver operating characteristic curve (tAUC) at 6 months of 0·84 (0·83-0·85) for all-cause mortality, 0·70 (0·68-0·73) for major bleeding, and 0·79 (0·78-0·81) for ischaemic events on internal validation. On external validation, ONCO-ACS achieved similar performance for all-cause mortality (tAUC at 6 months 0·84 [0·82-0·85] for the English Midlands, 0·80 [0·79-0·82] for Sweden, and 0·83 [0·76-0·91] for Switzerland), major bleeding events (0·70 [0·67-0·74] for the English Midlands, 0·67 [0·65-0·70] for Sweden, and 0·74 [0·57-0·91] for Switzerland), and ischaemic events (0·76 [0·74-0·78] for the English Midlands, 0·70 [0·69-0·72] for Sweden, and 0·73 [0·61-0·86] for Switzerland). ONCO-ACS was well calibrated and decision curve analyses suggested favourable clinical utility. Applying ONCO-ACS to current guidelines suggests that most patients with cancer and acute coronary syndrome qualify for invasive management and long dual antiplatelet therapy using clopidogrel. INTERPRETATION: The ONCO-ACS score provides a validated practical tool for predicting mortality, bleeding, and ischaemic risk in patients with cancer and acute coronary syndrome. Combined assessment of competing outcome risks could facilitate balancing treatment benefits and harms. FUNDING: British Heart Foundation, Cancer Research UK, Swiss Heart Foundation, University of Zurich Foundation, Kurt-Senta-Herrmann Foundation, Theodor-Ida-Herzog-Egli Foundation, Foundation for Cardiovascular Research-Zurich Heart House, Swedish ALF Research Funds.
Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022 Mohan Satish, Ryan W. Walters, Florian A. Wenzl, Monika Safford, Vinay Kini Journal of the American Heart Association, 2026 Background Acute myocardial infarction (AMI) hospitalizations are increasing in young adults, but outcomes stratified by sex and AMI subtype are not well understood. Methods First AMI hospitalizations among young adults 18 to 54 years old were analyzed from 2011 to 2022 in the United States from the National Inpatient Sample and stratified by subtype (ST‐segment–elevation myocardial infarction [STEMI] and non–ST‐segment–elevation myocardial infarction) and sex. In‐hospital mortality by first AMI‐subtype was the primary outcome, including in‐hospital mortality trends using orthogonal polynomial contrasts; in‐hospital complications were secondary outcomes. Patient characteristics included traditional and nontraditional risk factors. All analyses were performed sex‐stratified with adjustment using a sequential additive multivariable logistic regression model. Results Among 945 977 weighted first AMI hospitalizations in young adults, 356 115 (37.6%) were STEMI and 589 862 (62.4%) were non–ST‐segment–elevation myocardial infarction. Overall, adjusted in‐hospital mortality increased significantly for first STEMI (1.2% absolute increase, P trend <0.001) and was unchanged for first non–ST‐segment–elevation myocardial infarction (0.2% absolute decrease, P trend =0.70) across the study period. Compared with young men, young women had higher in‐hospital mortality compared with young men (STEMI: 3.1% versus 2.6%, P <0.001; non–ST‐segment–elevation myocardial infarction: 1.0% versus 0.8%, P =0.03) and experienced similar in‐hospital complications with lower receipt of cardiovascular procedures. Irrespective of sex, more nontraditional than traditional risk factors were independently associated with higher odds of in‐hospital mortality. Conclusions There was a rise in first STEMI in‐hospital mortality among young adults from 2011 to 2022. Mortality for both AMI subtypes was higher in young women and was associated with more nontraditional compared with traditional risk factors.
Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours a systematic review and meta-analysis Maria A. Smolle, Florian A. Wenzl, Minna K. Laitinen, Lee M. Jeys, Andreas Leithner Bone and Joint Open, 2026 Aims Surgical management of intermediate and malignant tumours in the pelvis is complex. Complications are frequent and either related to the surgery itself or to post-surgical failure of the reconstruction technique. This systematic review and meta-analysis aims at analyzing all reported complications following PI to PIII pelvic resections for intermediate and malignant tumours. Methods Based on a systematic literature search on PubMed adhering to the PRISMA guidelines, 1,683 study records were identified, of which we included 90 original studies published until 22 July 2025. Overall complication rates were assessed with random-effects meta-analysis. Differences in complication rates between reconstruction types (i.e. megaprosthetic, mostly biological, none) were evaluated with meta regression analysis. Results Data on 2,199 patients (1,250 males (57%)) with mainly PI to PIII pelvic resections were analyzed. The most common reconstruction types were custom-made implants (21%; n = 451) and ice-cream cone prostheses (14%; n = 312). Pooled rates of infections, wound healing problems, nerve injuries, and deep vein thrombosis (DVT) amounted to 15% (95% CI 12% to 18%), 13% (95% CI 10% to 15%), 7% (95% CI 5% to 9%), and 4% (95% CI 2% to 6%), respectively. Further, pooled implant revision/removal and secondary external hemipelvectomy rates were 14% (95% CI 11% to 17%) and 4% (95% CI 3% to 5%). Mostly biological reconstructions were associated with higher rates of nerve injuries (p < 0.001), construct failures (p = 0.010), and secondary implant revision/removal (p = 0.003) compared to megaprosthetic reconstruction. Further, biological reconstructions were associated with increased secondary external hemipelvectomy rates compared to megaprosthetic reconstructions (p = 0.005) or no reconstructions (p = 0.001). Conclusion Treatment of pelvic malignancies is challenging, with technically demanding resections and complex reconstructions. Across all reconstruction techniques following sacrum-sparing pelvic resections, infections and wound healing problems are the most common complications, yet there is also a considerable proportion of patients with neurovascular complications and DVTs. Cite this article: Bone Jt Open 2026;7(6):713–723.
Extension of the GRACE score for non-ST-elevation acute coronary syndrome: a development and validation study in ten countries Florian A Wenzl, Klaus F Kofoed, Moa Simonsson, Gareth Ambler, Niels M R van der Sangen, Erik Lampa, Francesco Bruno, Mark A de Belder, Jiri Hlasensky, Matthias Mueller-Hennessen, Maria A Smolle, Peizhi Wang, José P S Henriques, Wouter J Kikkert, Henning Kelbæk, Luboš Bouček, Sergio Raposeiras-Roubín, Emad Abu-Assi, Jaouad Azzahhafi, Matthijs A Velders, Konstantinos Stellos, Thomas Engstrøm, Dean R P P Chan Pin Yin, Clive Weston, David Adlam, Hans Rickli, Evangelos Giannitsis, Dragana Radovanovic, Jiri Parenica, Charalambos A Antoniades, Keith A A Fox, Fabrizio D'Ascenzo, Jurriën M ten Berg, Lars V Køber, Stefan James, John Deanfield, Thomas F Lüscher Lancet Digital Health, 2025
Current and novel biomarkers in cardiogenic shock Victor Galusko, Florian A. Wenzl, Christophe Vandenbriele, Vasileios Panoulas, Thomas F. Lüscher, Diana A. Gorog European Journal of Heart Failure, 2025
Proenkephalin improves cardio-renal risk prediction in acute coronary syndromes: The KID-ACS score Florian A Wenzl, Peizhi Wang, Mattia Arrigo, Jiri Parenica, Donald J L Jones, Francesco Bruno, Daniel Tarnowski, Oliver Hartmann, Lubos Boucek, Fabian Lang, Slayman Obeid, Andreas Schober, Simon Kraler, Alexander Akhmedov, Florian Kahles, Alexander Schober, Kok Weng Ow, Stefano Ministrini, Giovanni G Camici, Andreas Bergmann, Luca Liberale, Jiri Jarkovsky, Victor Schweiger, Jatinderpal K Sandhu, Arnold von Eckardstein, Christian Templin, Olivier Muller, Tomas Ondrus, Janet-Jacqueline Olic, Marco Roffi, Lorenz Räber, Thong H Cao, Carsten G Jungbauer, Leong L Ng, Alexandre Mebazaa, Thomas F Lüscher European Heart Journal, 2025
Biomarker-enhanced cardiovascular risk prediction in patients with cancer: a prospective cohort study Simon Kraler, Luca Liberale, Stephan Nopp, Cornelia Englisch, Ella Grilz, Tetiana Lapikova-Bryhinska, Alexander Akhmedov, Federico Carbone, Davide Ramoni, Amedeo Tirandi, Alessandro Scuricini, Simone Isoppo, Curzia Tortorella, Federica La Rosa, Cristina Michelauz, Federica Frè, Aurora Gavoci, Anna Lisa, Thomas M. Suter, Arnold von Eckardstein, Florian A. Wenzl, Ingrid Pabinger, Thomas F. Lüscher, Fabrizio Montecucco, Cihan Ay, Florian Moik Journal of Thrombosis and Haemostasis, 2024
Temporal Trends in Takotsubo Syndrome: Results From the International Takotsubo Registry Victor Schweiger, Victoria L. Cammann, Giulia Crisci, Thomas Gilhofer, Rabea Schlenker, David Niederseer, Shaojie Chen, Ramin Ebrahimi, Florian Wenzl, Michael Würdinger, Rodolfo Citro, Carmine Vecchione, Sebastiano Gili, Michael Neuhaus, Jennifer Franke, Benjamin Meder, Miłosz Jaguszewski, Michel Noutsias, Maike Knorr, Thomas Jansen, Fabrizio D’Ascenzo, Wolfgang Dichtl, Dirk von Lewinski, Christof Burgdorf, Behrouz Kherad, Carsten Tschöpe, Annahita Sarcon, Jerold Shinbane, Lawrence Rajan, Guido Michels, Roman Pfister, Alessandro Cuneo, Claudius Jacobshagen, Mahir Karakas, Wolfgang Koenig, Alexander Pott, Philippe Meyer, Marco Roffi, Adrian Banning, Mathias Wolfrum, Florim Cuculi, Richard Kobza, Thomas A. Fischer, Tuija Vasankari, K.E. Juhani Airaksinen, L. Christian Napp, Rafal Dworakowski, Philip MacCarthy, Christoph Kaiser, Stefan Osswald, Leonarda Galiuto, Christina Chan, Paul Bridgman, Daniel Beug, Clément Delmas, Olivier Lairez, Ekaterina Gilyarova, Alexandra Shilova, Mikhail Gilyarov, Ibrahim El-Battrawy, Ibrahim Akin, Karolina Poledniková, Petr Toušek, David E. Winchester, Michael Massoomi, Jan Galuszka, Christian Ukena, Gregor Poglajen, Pedro Carrilho-Ferreira, Christian Hauck, Carla Paolini, Claudio Bilato, Yoshio Kobayashi, Ken Kato, Iwao Ishibashi, Toshiharu Himi, Jehangir Din, Ali Al-Shammari, Abhiram Prasad, Charanjit S. Rihal, Kan Liu, P. Christian Schulze, Matteo Bianco, Lucas Jörg, Hans Rickli, Gonçalo Pestana, Thanh H. Nguyen, Michael Böhm, Lars S. Maier, Fausto J. Pinto, Petr Widimský, Stephan B. Felix, Ruediger C. Braun-Dullaeus, Wolfgang Rottbauer, Gerd Hasenfuß, Burkert M. Pieske, Heribert Schunkert, Monika Budnik, Grzegorz Opolski, Holger Thiele, Johann Bauersachs, John D. Horowitz, Carlo Di Mario, William Kong, Mayank Dalakoti, Yoichi Imori, Thomas Münzel, Luca Liberale, Fabrizio Montecucco, Jeroen J. Bax, Filippo Crea, Frank Ruschitzka, Thomas F. Lüscher, Jelena R. Ghadri, Eduardo Bossone, Christian Templin, Davide Di Vece Journal of the American College of Cardiology, 2024
Circulating GDF11 exacerbates myocardial injury in mice and associates with increased infarct size in humans Simon Kraler, Carolina Balbi, Daria Vdovenko, Tetiana Lapikova-Bryhinska, Giovanni G Camici, Luca Liberale, Nicole Bonetti, Candela Diaz Canestro, Fabienne Burger, Aline Roth, Federico Carbone, Giuseppe Vassalli, François Mach, Shalender Bhasin, Florian A Wenzl, Olivier Muller, Lorenz Räber, Christian M Matter, Fabrizio Montecucco, Thomas F Lüscher, Alexander Akhmedov Cardiovascular Research, 2023
Modification of the GRACE Risk Score for Risk Prediction in Patients with Acute Coronary Syndromes Georgios Georgiopoulos, Simon Kraler, Matthias Mueller-Hennessen, Dimitrios Delialis, Georgios Mavraganis, Kateryna Sopova, Florian A. Wenzl, Lorenz Räber, Moritz Biener, Barbara E. Stähli, Eleni Maneta, Luke Spray, Juan F. Iglesias, Jose Coelho-Lima, Simon Tual-Chalot, Olivier Muller, François Mach, Norbert Frey, Daniel Duerschmied, Harald F. Langer, Hugo Katus, Marco Roffi, Giovanni G. Camici, Christian Mueller, Evangelos Giannitsis, Ioakim Spyridopoulos, Thomas F. Lüscher, Konstantinos Stellos, Kimon Stamatelopoulos JAMA Cardiology, 2023
Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes Florian A Wenzl, Francesco Bruno, Simon Kraler, Roland Klingenberg, Alexander Akhmedov, Stefano Ministrini, Karine Santos, Konstantin Godly, Julia Godly, David Niederseer, Robert Manka, Andreas Bergmann, Giovanni G Camici, Arnold von Eckardstein, Barbara Stähli, Olivier Muller, Marco Roffi, Lorenz Räber, Thomas F Lüscher European Heart Journal, 2023
Initial systolic blood pressure associates with systemic inflammation, myocardial injury, and outcomes in patients with acute coronary syndromes Patric A Winzap, Simon Kraler, Slayman Obeid, Florian A Wenzl, Christian Templin, Roland Klingenberg, Arnold von Eckardstein, Marco Roffi, Olivier Muller, Lorenz Räber, Thomas F Lüscher, SPUM-ACS investigators, F Mach, C Matter, N Rodondi, D Nanchen, D Carballo, B Gencer, Matthias Pfisterer, Lukas Kappenberger, Tiziano Moccetti, Philippe Meyer, Pascal Meier, Juan Iglesias, Fabio Rigamonti, Carola Kälin-Weeke, Isabelle Peereboom, Monika Seiler European Heart Journal Acute Cardiovascular Care, 2023
Penetrating arteriovenous fistulas: Uncommon and challenging entities Juan A. Asensio, John J. Kessler, Parinaz J. Dabestani, Stephanie S. Miljkovic, Florian A. Wenzl, Tharun R. Kotaru, Louay D. Kalamchi, Arthur P. Sanford Current Therapy of Trauma and Surgical Critical Care, 2023
Penetrating extracranial vertebral artery injuries Vincent L. Rowe, Juan A. Asensio, Parinaz J. Dabestani, John J. Kessler, Florian A. Wenzl, Stephanie S. Miljkovic, Tharun R. Kotaru, Louay D. Kalamchi, Tyson Becker, Carlos Fernandez, David Cornell Current Therapy of Trauma and Surgical Critical Care, 2023
Popliteal vessel injuries: Complex anatomy and high amputation rates Juan A. Asensio, Parinaz J. Dabestani, John J. Kessler, Stephanie S. Miljkovic, Tharun R. Kotaru, Louay D. Kalamchi, Elliot J. Jessie, Jeremy W. Cannon, Florian A. Wenzl, Matthew Bradley, Ashley Humphries, Luis Manuel García-Núñez Current Therapy of Trauma and Surgical Critical Care, 2023
Brachial vessel injuries: High morbidity and low mortality injuries Alejandro Perez-Alonso, Juan A. Asensio, Parinaz J. Dabestani, John J. Kessler, Stephanie S. Miljkovic, Tharun R. Kotaru, Louay D. Kalamchi, Joseph S. Fernandez-Moure, George Kasotakis, Suresh Agarwal, Florian A. Wenzl, Travis Polk, Dan Grabo Current Therapy of Trauma and Surgical Critical Care, 2023
Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes Simon Kraler, Florian A Wenzl, Georgios Georgiopoulos, Slayman Obeid, Luca Liberale, Arnold von Eckardstein, Olivier Muller, François Mach, Lorenz Räber, Sylvain Losdat, Martin O Schmiady, Konstantinos Stellos, Kimon Stamatelopoulos, Giovanni G Camici, Annie Srdic, Francesco Paneni, Alexander Akhmedov, Thomas F Lüscher European Heart Journal, 2022
Traumatic penetrating arteriovenous fistulas: a collective review Juan A. Asensio, Parinaz J. Dabestani, Stephanie S. Miljkovic, Florian A. Wenzl, John J. Kessler, Louay D. Kalamchi, Tharun R. Kotaru, Devendra K. Agrawal European Journal of Trauma and Emergency Surgery, 2022
Inflammation in metabolic cardiomyopathy Florian A. Wenzl, Samuele Ambrosini, Shafeeq A. Mohammed, Simon Kraler, Thomas F. Lüscher, Sarah Costantino, Francesco Paneni Frontiers in Cardiovascular Medicine, 2021
A systematic review of penetrating extracranial vertebral artery injuries Juan A. Asensio, Parinaz J. Dabestani, Florian A. Wenzl, Stephanie S. Miljkovic, John J. Kessler, Carlos A. Fernandez, Tyson Becker, David Cornell, Margaret Siu, Charles Voigt, Devendra K. Agrawal Journal of Vascular Surgery, 2020
RECENT SCHOLAR PUBLICATIONS
Multi-biomarker approach for predicting cardiac magnetic resonance parameters at 30 days after ST-segment elevation myocardial infarction T Horbach, FA Wenzl, R Manka, L Räber, D Carballo, T Keller, S Sossalla, ... IJC Heart & Vasculature 64, 101918 , 2026 2026
Cancer and cardiovascular disease: converging burdens, shared challenges FA Wenzl, AR Lyon, D Adlam European Heart Journal, ehag141 , 2026 2026
Novel treatment strategies in cardiogenic shock: an update on ongoing clinical trials M Padilla-Lopez, F Manicone, SLD Holle, FA Wenzl, A Kimmoun, ... Heart Failure Reviews 31 (1), 64 , 2026 2026
Refined outcome prediction in patients with extremity soft tissue sarcoma MA Smolle, FA Wenzl, A Leithner The Lancet Oncology 27 (5), 533-534 , 2026 2026
Nationwide treatment patterns and outcomes of localised soft tissue sarcoma in Austria: real-world data from the Austrian Sarcoma Registry MA Smolle, S Hasenschwandtner, A Reichinger, G Koulaxouzidis, ... Journal of Orthopaedic Surgery and Research , 2026 2026
C-reactive protein and cardiovascular risk in the general population B Kurt, M Reugels, KM Schneider, J Spiesshoefer, A Milzi, A Gombert, ... European heart journal 47 (15), 1799-1810 , 2026 2026 Citations: 29
Genetic Variation in Clinical Cohorts MA Smolle, FA Wenzl New England Journal of Medicine 394 (11), 1141-1142 , 2026 2026
Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022 M Satish, RW Walters, FA Wenzl, M Safford, V Kini Journal of the American Heart Association 15 (5), e046517 , 2026 2026 Citations: 1
Immediate versus staged complete revascularization in a real-world cohort of patients with ST-elevation myocardial infarction and multivessel disease A Denegri, F Bruno, S Kraler, F Wenzl, M Roffi, TF Luescher European Heart Journal Supplements 28 (Supplement_3), suag056. 046 , 2026 2026
Natriuretic peptide dynamics predict long-term outcomes after TAVI FA Wenzl, P Wang, P Savvoulidis, Q Chen, T Al-Och, H Yakup Yakupoglu, ... European Heart Journal Supplements 28 (Supplement_3), suag056. 078 , 2026 2026
Interpreting the GRACE 3.0 ITE model: from predictive performance to clinical decision utility FA Wenzl, LV Køber, S James, JE Deanfield, TF Lüscher The Lancet Digital Health 8 (3) , 2026 2026
Beta-Blockers after Myocardial Infarction—Toward Personalized Management TF Lüscher, FA Wenzl New England Journal of Medicine 394 (6), 599-602 , 2026 2026 Citations: 2
Personalized Management of Acute Coronary Syndromes FA Wenzl Dissertation, University of Zurich) https://doi. org/10.5167/uzh-284479 , 2026 2026
Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study FA Wenzl, KW Ow, MA Velders, F Tyrer, L Paley, J Lai, MA Smolle, ... The Lancet 407 (10527), 515-528 , 2026 2026 Citations: 4
Smoking cessation after acute myocardial infarction: a prospective nationwide cohort study in Switzerland J Loosli, F Foster-Witassek, FA Wenzl, H Rickli, D Radovanovic European Journal of Preventive Cardiology, zwag048 , 2026 2026 Citations: 1
Interleukin-6 predicts cardiovascular events beyond standard modifiable risk factors in individuals without atherosclerotic cardiovascular disease M Reugels, B Kurt, KM Schneider, FA Wenzl, CB Fordyce, NJ Pagidipati, ... SPRINGER MEDIZIN VERLAG GmBH , 2026 2026
Impact of a recent cancer diagnosis on bleeding risk after myocardial infarction KW Ow, F Tyrer, F Van Den Berg, J Lai, S Vernon, L Paley, FA Wenzl, ... Heart , 2025 2025 Citations: 1
Gut microbiota-derived imidazole propionate is a novel marker of cardiometabolic risk in patients with coronary artery disease FA Wenzl, P Wang, K Beck, S Obeid, F Bruno, D Nanchen, L Liberale, ... European Heart Journal 46 (Supplement_1), ehaf784. 1947 , 2025 2025
Trends in early reperfusion therapy in non-ST-elevation myocardial infarction patients treated with PCI F Foster-Witassek, J Loosli, H Rickli, M Roffi, G Pedrazzini, F Wenzl, ... European Heart Journal 46 (Supplement_1), ehaf784. 2132 , 2025 2025
Interleukin-6 inclusion adds value to the SMART risk score for prediction of cardiovascular death in patients with established ASCVD B Kurt, M Reugels, KM Schneider, M Kleber, FA Wenzl, H Shimokawa, ... European Heart Journal 46 (Supplement_1), ehaf784. 3621 , 2025 2025
MOST CITED SCHOLAR PUBLICATIONS
Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational … FA Wenzl, S Kraler, G Ambler, C Weston, SA Herzog, L Räber, O Muller, ... The Lancet 400 (10354), 744-756 , 2022 2022 Citations: 162
Artificial intelligence in cardiovascular medicine: clinical applications TF Lüscher, FA Wenzl, F D’Ascenzo, PA Friedman, C Antoniades European heart journal 45 (40), 4291-4304 , 2024 2024 Citations: 159
Inflammation in metabolic cardiomyopathy FA Wenzl, S Ambrosini, SA Mohammed, S Kraler, TF Lüscher, ... Frontiers in Cardiovascular Medicine 8, 742178 , 2021 2021 Citations: 118
Modification of the GRACE risk score for risk prediction in patients with acute coronary syndromes G Georgiopoulos, S Kraler, M Mueller-Hennessen, D Delialis, ... JAMA cardiology 8 (10), 946-956 , 2023 2023 Citations: 66
Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes S Kraler, FA Wenzl, G Georgiopoulos, S Obeid, L Liberale, ... European heart journal 43 (19), 1849-1860 , 2022 2022 Citations: 64
Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes FA Wenzl, F Bruno, S Kraler, R Klingenberg, A Akhmedov, S Ministrini, ... European heart journal 44 (38), 3859-3871 , 2023 2023 Citations: 56
Temporal trends in takotsubo syndrome: results from the International Takotsubo Registry V Schweiger, VL Cammann, G Crisci, T Gilhofer, R Schlenker, ... Journal of the American College of Cardiology 84 (13), 1178-1189 , 2024 2024 Citations: 42
The BET protein inhibitor apabetalone rescues diabetes-induced impairment of angiogenic response by epigenetic regulation of thrombospondin-1 SA Mohammed, M Albiero, S Ambrosini, E Gorica, G Karsai, ... Antioxidants & Redox Signaling 36 (10-12), 667-684 , 2022 2022 Citations: 40
A systematic review of penetrating extracranial vertebral artery injuries JA Asensio, PJ Dabestani, FA Wenzl, SS Miljkovic, JJ Kessler II, ... Journal of vascular surgery 71 (6), 2161-2169 , 2020 2020 Citations: 39
Traumatic penetrating arteriovenous fistulas: a collective review JA Asensio, PJ Dabestani, SS Miljkovic, FA Wenzl, JJ Kessler, ... European Journal of Trauma and Emergency Surgery 48 (2), 775-789 , 2022 2022 Citations: 36
A systematic review and individual patient data meta-analysis of heart failure as a rare complication of traumatic arteriovenous fistulas FA Wenzl, SS Miljkovic, PJ Dabestani, JJ Kessler II, TR Kotaru, ... Journal of Vascular Surgery 73 (3), 1087-1094. e8 , 2021 2021 Citations: 34
Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial. S Kraler, FA Wenzl, TF Lüscher European journal of clinical investigation 50 (12) , 2020 2020 Citations: 34
Popliteal artery injuries. Less ischemic time may lead to improved outcomes JA Asensio, PJ Dabestani, SS Miljkovic, TR Kotaru, JJ Kessler, ... Injury 51 (11), 2524-2531 , 2020 2020 Citations: 33
C-reactive protein and cardiovascular risk in the general population B Kurt, M Reugels, KM Schneider, J Spiesshoefer, A Milzi, A Gombert, ... European heart journal 47 (15), 1799-1810 , 2026 2026 Citations: 29
Circulating GDF11 exacerbates myocardial injury in mice and associates with increased infarct size in humans S Kraler, C Balbi, D Vdovenko, T Lapikova-Bryhinska, GG Camici, ... Cardiovascular research 119 (17), 2729-2742 , 2023 2023 Citations: 27
Low-density lipoprotein electronegativity and risk of death after acute coronary syndromes: a case-cohort analysis S Kraler, FA Wenzl, J Vykoukal, JF Fahrmann, MY Shen, DY Chen, ... Atherosclerosis 376, 43-52 , 2023 2023 Citations: 27
Current and novel biomarkers in cardiogenic shock V Galusko, FA Wenzl, C Vandenbriele, V Panoulas, TF Lüscher, ... European Journal of Heart Failure 27 (6), 1106-1125 , 2025 2025 Citations: 26
Short and medium chain acylcarnitines as markers of outcome in diabetic and non-diabetic subjects with acute coronary syndromes A Davies, FA Wenzl, XS Li, P Winzap, S Obeid, R Klingenberg, F Mach, ... International journal of cardiology 389, 131261 , 2023 2023 Citations: 21
Occlusion of the infarct-related coronary artery presenting as acute coronary syndrome with and without ST-elevation: impact of inflammation and outcomes in a real-world … F Bruno, B Adjibodou, S Obeid, SC Kraler, FA Wenzl, MM Akhtar, ... European Heart Journal-Quality of Care and Clinical Outcomes 9 (6), 564-574 , 2023 2023 Citations: 20
Trajectories of cardiovascular ageing—from molecular mechanisms to clinical implementation S Ministrini, FA Wenzl, TF Lüscher, GG Camici Cardiovascular Research 121 (10), 1509-1523 , 2025 2025 Citations: 18
